Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven brokerages that are presently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $58.20.

MIRM has been the topic of several research analyst reports. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th.

Mirum Pharmaceuticals Stock Up 2.5 %

Shares of NASDAQ:MIRM traded up $0.98 during mid-day trading on Friday, reaching $40.60. 40,386 shares of the stock were exchanged, compared to its average volume of 522,219. The company has a market cap of $2.01 billion, a P/E ratio of -20.10 and a beta of 1.00. The stock's 50 day simple moving average is $44.55 and its 200-day simple moving average is $43.94. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Activity

In related news, CEO Christopher Peetz sold 6,837 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $327,629.04. Following the sale, the chief executive officer now owns 125,022 shares of the company's stock, valued at $5,991,054.24. The trade was a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Peter Radovich sold 7,879 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the transaction, the chief operating officer now owns 18,672 shares of the company's stock, valued at $825,489.12. This trade represents a 29.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,473 shares of company stock valued at $5,249,134. 22.87% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of Mirum Pharmaceuticals by 4.6% in the third quarter. Barclays PLC now owns 245,918 shares of the company's stock worth $9,592,000 after purchasing an additional 10,824 shares during the period. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after purchasing an additional 29,017 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in Mirum Pharmaceuticals during the third quarter worth about $28,913,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 25.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after purchasing an additional 29,545 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $189,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.